Don’t miss – Page 121 – Endpoints News

SIGN UP

A name emerges out of the Gilead M&A rumor mill, and it’s a cancer biotech

3 years ago

Biogen makes another bold Alzheimer’s bet, dropping $350M upfront to partner with genome-editing focused Sangamo

3 years ago

A 9/11-era Omaha facility, an old Ebola drug, and the ubiquitous Dr. Fauci: Inside the first US novel coronavirus trial

3 years ago

Spark loses another top exec in the wake of $4.3B takeover by Roche — report

3 years ago

'The headlines are the headlines, but': BioMarin talks up potential savings as hemophilia gene therapy launch looms

3 years ago

In at least one life-sci hub, gender and diversity initiatives haven’t made a dent

3 years ago

Microbiome Q&A: New study maps the vagina's 'optimal microbiota' — and its implications for biopharma

3 years ago

Takeda swoops in to buy little biotech partner and its celiac drug poised to 'change standard of care'

3 years ago

Theft victim or data bully? IQVIA exchanges blows with small rival it says destroyed evidence in legal fight

3 years ago

Biogen touts new evidence from the gene therapy company it wagered $800M on

3 years ago

Bicycle Therapeutics takes Roche's Genentech on an up to $2B immuno-oncology ride

3 years ago

NIH-partnered Moderna ships off its PhI-ready coronavirus vaccine candidate to a sea of uncertainty

3 years ago

Novartis' plans to wrestle Eylea market share take a hit as Beovu is linked to safety concerns

3 years ago

NGM Bio takes leap forward in crowded NASH field

3 years ago

Novartis gets a boost in blockbuster multiple sclerosis race with Roche

3 years ago

The fourth CGRP migraine drug is here. Time for Lundbeck to prove it's worth $2B

3 years ago

Esperion's goldilocks cholesterol fighter wins FDA approval — will its 'traditional' pricing approach spur adoption?

3 years ago

A space odyssey for new antibiotics: MIT's machine learning approach

3 years ago

Gilead loses two more patent challenges on HIV pill, setting up courtroom fight in Delaware

3 years ago

Speedy review and no adcomm for BioMarin's pioneering hemophilia gene therapy

3 years ago

Gene therapy pioneer Kathy High has left Spark after completing $4.3B union with Roche

3 years ago

Merck loses its chief digital officer, spotlighting talent hunt for the hottest title in Big Pharma

3 years ago

Don't let AbbVie fool FTC with an easy divestiture, plead critics in latest attack on $63B Allergan buyout

3 years ago

Austedo, Teva's bright spot as it executes turnaround, fails two Tourette's trials

3 years ago

First page Previous page 118 119 120121122 123 124 Next page Last page